Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:52 2024-06-07 am EDT 		5-day change 1st Jan Change
208.2 SEK +0.19% Intraday chart for Calliditas Therapeutics AB +0.10% +63.81%
Jun. 07 European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
Jun. 06 Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT

Evolution of the average Target Price on Calliditas Therapeutics AB

Price target over the last 5 years

History of analyst recommendation changes

572e5593a5da7.TCQX3hWTfwBGlCNezcqQrl65ZcUElJ8DoM4HFtd_sjs.JFNYvFbBGEUk03kXgaX1x23KPIpo98Zi85lyYvod3WgTRjqpQsoHZizDag~f92073011a85ae507f4bcb6269f6a806

Analyst Recommendations on Calliditas Therapeutics AB

Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 MT
HC Wainwright Downgrades Calliditas Therapeutics to Neutral From Buy, Cuts Price Target to $39 From $45 MT
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55 MT
HC Wainwright Cuts Calliditas Therapeutics Price Target to $45 From $50, Maintains Buy Rating MT
Guggenheim Adjusts Calliditas Therapeutics' Price Target to $18 From $21, Keeps Neutral Rating MT
HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target MT
Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target MT
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates Buy Rating MT
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy Rating MT
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company... Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
207.8 SEK
Average target price
219.8 SEK
Spread / Average Target
+5.75%
High Price Target
270 SEK
Spread / Highest target
+29.93%
Low Price Target
171 SEK
Spread / Lowest Target
-17.71%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Calliditas Therapeutics AB

Citigroup
Stifel Nicolaus
HC Wainwright
Guggenheim

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. Consensus Calliditas Therapeutics AB